Chengdu Olymvax Biopharmaceuticals (688319) Fundamentals 2026 — P/E 192.8x, Revenue Analysis | SniperIQ
Chengdu Olymvax Biopharmaceuticals (688319) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥10.9B, trading at ¥26.92 on the SHH. This SniperIQ fundamentals page covers Chengdu Olymvax Biopharmaceuticals's valuation (P/E 192.8x, P/B 11.7x), profitability (net margin 7.3%), revenue (¥704M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chengdu Olymvax Biopharmaceuticals's market cap?
Chengdu Olymvax Biopharmaceuticals (688319) has a market capitalization of approximately ¥10.9B, trading at ¥26.92 on the SHH. Market cap moves with the live share price.
What is Chengdu Olymvax Biopharmaceuticals's P/E ratio?
Chengdu Olymvax Biopharmaceuticals's trailing twelve-month P/E ratio is 192.8x, with a price-to-book (P/B) of 11.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chengdu Olymvax Biopharmaceuticals?
Chengdu Olymvax Biopharmaceuticals runs a net profit margin of 7.3%, a gross margin of 99.1%, and an operating margin of 9.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chengdu Olymvax Biopharmaceuticals generate?
Chengdu Olymvax Biopharmaceuticals reported revenue of ¥704M for fiscal year 2025, with net income of ¥22M and earnings per share (EPS) of 0.0548. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chengdu Olymvax Biopharmaceuticals pay a dividend?
Chengdu Olymvax Biopharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Chengdu Olymvax Biopharmaceuticals financially healthy?
Chengdu Olymvax Biopharmaceuticals carries a debt-to-equity ratio of 0.47x and a current ratio of 1.36x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chengdu Olymvax Biopharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chengdu Olymvax Biopharmaceuticals (688319) the key facts are: market cap ¥10.9B, P/E 192.8x, revenue ¥704M, 52-week range 19.99-44.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chengdu Olymvax Biopharmaceuticals's full fundamentals live
Get Chengdu Olymvax Biopharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.